·前   言
·公   司
·发展历史
·新闻
·观念体系
·管理和策略
·生产厂房
·产品和种类
·产品市场
·员   工
·质   量
·产品的安全性
·环   境
·联系方式
·ENGLISH
                             
  当前主题共2下一页
     

As China becomes one of the world’s largest economies, the domestic demand of high quality biopharmaceutical products has dramatically grown in recently years. Ten years ago, only a few thousands flu shots were applied, but in year 2005, about 20 million flu shots were administered. We expect this trend to continue in the future.

China has the world’s largest population of 1.4 billion and already ranks No. 4 in the world vaccine market (after US, Germany, and Japan), and there is no doubt that it will be the world’s largest market for biopharmaceutical products.

Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd has sales network that covers 9 representative offices in China and could supply vaccines directly to 30 provinces in China. About 80 sales people are part of our sales network

随着中国日益成为世界经济大国,近几年国内对高品质生物制品的需求大幅度增长。十年前,还只是使用几千支流感疫苗,到了2005年,已经使用了二千万支流感疫苗。我们希望这一趋势还将继续。

中国拥有14亿人口,是世界第一人口大国,它在世界疫苗市场中位居第四(排在美国,德国和日本之后)。毫无疑问中国将成为生物制品最大的销售市场。

浙江天元生物药业股份有限公司的9个销售处,遍布中国30个省,市,自治区,共有80余名销售精英负责公司的销售网络。


 

 

 

 

 

 

 


当前主题共2下一页
 
浙江天元生物药业股份有限公司 版权所有(C)2007,网络支持 中国医药网 生意宝